Avenue Therapeutics Announces Reverse Stock Split
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company […]
HighPeak Energy, Inc. Announces 2024 First Quarter Earnings Release and Conference Call Dates
FORT WORTH, Texas, April 24, 2024 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it […]
Grab to Announce First Quarter 2024 Results on May 15, 2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB, the “Company” or “Grab”), plans to announce […]
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with […]
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary […]
Tower Semiconductor Announces First Quarter 2024 Financial Results and Conference Call
MIGDAL HAEMEK, Israel – April 24, 2024 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high-value analog semiconductor […]
Futu Announces the Number of Its Clients in Malaysia Has Surpassed 100,000
HONG KONG, April 24, 2024 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online […]
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary […]
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, […]
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase […]
